GHRL and breast carcinoma: Increased risks were also observed in the co-dominant model of breast cancer studies for the rs4684677 GHRL SNP (OR 1.11, p = 0.23) and the GHSR rs572169 SNP, both overall and in breast cancer (OR 1.08-1.10), with borderline significance (p = 0.05), all homogeneously obtained (I2 = 0-46%).